None Side Effect High-Potency Fluocinonide for Skin Disorders

1.Quick Details:

Name:Fluocinonide

Fluocinonide Synonyms: 1,4-PREGNADIEN-6-ALPHA, 9-ALPHA-DIFLUORO-11-BETA, 16-ALPHA, 17,21-TETROL-3,20-DIONE 16,17-ACETONIDE 21-ACETATE;FLUOCINOLONE ACETONIDE 21-ACETATE;FLUOCINOMIDE;FLUOCINONIDE;FLUOCINONIDE ACETONIDE 21-ACETATE;

CAS: 356-12-7 

MF: C26H32F2O7  MW: 494.52 

EINECS: 206-597-6 

Product Categories: Steroids;Intermediates & Fine Chemicals;Pharmaceuticals;

LIDEX;Inhibitors

MP 309 °C 

Storage temp.  Refrigerator 

Chemical Properties White Solid 

Package:1kg/foil bag or as your inquiry 

HS code:2914400000

Usage : Antiinflammatory, glucocorticoid.Glucocorticoid; anti-inflammatory.  

Reference FOB Price:$1/g

MOQ:1kg

Specification:ISO9001,USP,BP,GMP

Trade Mark:CQSP

Port:Shenzhen/Shanghai,China

Production Capacity:5000kg/month

More details pls contact:Whatapp:86 13048470428  

Skype/E-mail : summer at chembj.com

2. Clinical Pharmacology

Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. 

The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and the therapeutic efficacy in man. 

Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. 

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses. 

3. Dosage

Fluocinonide cream 0.05% is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. 

Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. 

If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted. 

4. Overdose

Topically applied corticosteroids can be absorbed in sufficient amount to produce systemic effects (see PRECAUTIONS). 

5. Precautions

General: 

 Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. 

Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. 

Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. 

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. 

Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted. 

As with any topical corticosteroid product, prolonged use may produce atrophy of the skin and subcutaneous tissues. When used on intertriginous or flexor areas, or on the face, this may occur even with short term use. 

In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.